| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Gynecologic Oncology,* University of Texas M.D. Anderson Cancer Center, Houston, Texas; the Departments of Anatomy and Cell Biology and Pathology, the Dows Institute for Dental Research, and the Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa Hospitals and Clinics, Iowa City, Iowa; and the Department of Cell and Developmental Biology and Lineberger Comprehensive Cancer Center,¶ University of North Carolina, Chapel Hill, North Carolina
Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that is activated by integrin clustering. There are limited data regarding the functional role of FAK in ovarian cancer migration and invasion. In the current study, FAK expression was evaluated in ovarian cell lines (nontransformed and cancer), 12 benign ovarian samples, and in 79 invasive epithelial ovarian cancers. All three ovarian cancer cell lines overexpressed FAK compared to the nontransformed cells. The dominant-negative construct called FAK-related nonkinase (FRNK) was introduced into two ovarian cancer cell lines (SKOV3 and 222). FRNK promoted FAK dephosphorylation without changing total FAK levels in these cell lines. Furthermore, FRNK decreased the in vitro invasive ability of ovarian cancer cells by 56 to 85% and decreased migration by 52 to 68%. FRNK-transfected cells also displayed poor cell spreading. Immunohistochemical analysis revealed that the surface epithelium from all benign ovarian samples had weak FAK expression. In contrast, 68% of invasive ovarian cancers overexpressed FAK. FAK overexpression was significantly associated with high tumor stage, high tumor grade, positive lymph nodes and presence of distant metastasis (all P values <0.05). FAK overexpression was also associated with shorter overall survival (P = 0.008). Multivariate analysis revealed that FAK overexpression and residual disease >1 cm were independent predictors of poor survival. These data indicate that FAK is overexpressed in most invasive ovarian cancers and plays a functionally significant role in ovarian cancer migration and invasion. Thus, FAK may be an important therapeutic target in ovarian carcinoma.
This article has been cited by other articles:
 |
|
 |
|
  J. Y. Hwang, L. S. Mangala, J. Y. Fok, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, D. J. Fiterman, P. E. Vivas-Mejia, M. T. Deavers, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma Cancer Res., July 15, 2008; 68(14): 5849 - 5858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Watanabe, M. Takaoka, K. Sakurama, Y. Tomono, S. Hatakeyama, O. Ohmori, T. Motoki, Y. Shirakawa, T. Yamatsuji, M. Haisa, et al. Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma In vitro and In vivo Clin. Cancer Res., July 15, 2008; 14(14): 4631 - 4639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, A. M. Urvalek, J. Liu, and J. Zhao Activation of KLF8 Transcription by Focal Adhesion Kinase in Human Ovarian Epithelial and Cancer Cells J. Biol. Chem., May 16, 2008; 283(20): 13934 - 13942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Halder, Y. G. Lin, W. M. Merritt, W. A. Spannuth, A. M. Nick, T. Honda, A. A. Kamat, L. Y. Han, T. J. Kim, C. Lu, et al. Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma Cancer Res., November 15, 2007; 67(22): 10976 - 10983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Barbolina, B. P. Adley, E. V. Ariztia, Y. Liu, and M. S. Stack Microenvironmental Regulation of Membrane Type 1 Matrix Metalloproteinase Activity in Ovarian Carcinoma Cells via Collagen-induced EGR1 Expression J. Biol. Chem., February 16, 2007; 282(7): 4924 - 4931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lu, T. Bonome, Y. Li, A. A. Kamat, L. Y. Han, R. Schmandt, R. L. Coleman, D. M. Gershenson, R. B. Jaffe, M. J. Birrer, et al. Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma Cancer Res., February 15, 2007; 67(4): 1757 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Rodrigo, F. Dominguez, V. Suarez, M. Canel, P. Secades, and M. D. Chiara Focal Adhesion Kinase and E-Cadherin as Markers for Nodal Metastasis in Laryngeal Cancer Arch Otolaryngol Head Neck Surg, February 1, 2007; 133(2): 145 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Halder, A. A. Kamat, C. N. Landen Jr., L. Y. Han, S. K. Lutgendorf, Y. G. Lin, W. M. Merritt, N. B. Jennings, A. Chavez-Reyes, R. L. Coleman, et al. Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy. Clin. Cancer Res., August 15, 2006; 12(16): 4916 - 4924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Mon, H. Hasegawa, A. A. Thant, P. Huang, Y. Tanimura, T. Senga, and M. Hamaguchi A Role for Focal Adhesion Kinase Signaling in Tumor Necrosis Factor-{alpha}-Dependent Matrix Metalloproteinase-9 Production in a Cholangiocarcinoma Cell Line, CCKS1. Cancer Res., July 1, 2006; 66(13): 6778 - 6784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Bryant, Q. Zheng, and K. Pumiglia Focal Adhesion Kinase Controls Cellular Levels of p27/Kip1 and p21/Cip1 through Skp2-Dependent and -Independent Mechanisms. Mol. Cell. Biol., June 1, 2006; 26(11): 4201 - 4213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Canel, P. Secades, J.-P. Rodrigo, R. Cabanillas, A. Herrero, C. Suarez, and M.-D. Chiara Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clin. Cancer Res., June 1, 2006; 12(11): 3272 - 3279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Sood, R. Bhatty, A. A. Kamat, C. N. Landen, L. Han, P. H. Thaker, Y. Li, D. M. Gershenson, S. Lutgendorf, and S. W. Cole Stress Hormone-Mediated Invasion of Ovarian Cancer Cells Clin. Cancer Res., January 15, 2006; 12(2): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Halder, C. N. Landen Jr., S. K. Lutgendorf, Y. Li, N. B. Jennings, D. Fan, G. M. Nelkin, R. Schmandt, M. D. Schaller, and A. K. Sood Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells Clin. Cancer Res., December 15, 2005; 11(24): 8829 - 8836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bonome, J.-Y. Lee, D.-C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G. J. Gardner, K. Hao, W. H. Wong, J. C. Barrett, et al. Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary Cancer Res., November 15, 2005; 65(22): 10602 - 10612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Hess, L.-M. Postovit, N. V. Margaryan, E. A. Seftor, G. B. Schneider, R. E.B. Seftor, B. J. Nickoloff, and M. J.C. Hendrix Focal Adhesion Kinase Promotes the Aggressive Melanoma Phenotype Cancer Res., November 1, 2005; 65(21): 9851 - 9860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Fan, R. O. Jacamo, X. Jiang, J. Sinnett-Smith, and E. Rozengurt G Protein-coupled Receptor Activation Rapidly Stimulates Focal Adhesion Kinase Phosphorylation at Ser-843: MEDIATION BY Ca2+, CALMODULIN, AND Ca2+/CALMODULIN-DEPENDENT KINASE II J. Biol. Chem., June 24, 2005; 280(25): 24212 - 24220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. van Nimwegen, S. Verkoeijen, L. van Buren, D. Burg, and B. van de Water Requirement for Focal Adhesion Kinase in the Early Phase of Mammary Adenocarcinoma Lung Metastasis Formation Cancer Res., June 1, 2005; 65(11): 4698 - 4706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Stein Mechanogenomic Control of DNA Exposure and Sequestration Am. J. Pathol., April 1, 2005; 166(4): 959 - 962. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
